11.13.24 -- Neogene's Focus On Off-The-Shelf TCR Therapies

Learn about the key factors that influence qPCR reaction performance and provides guidelines for evaluating and comparing reactions run under varying conditions to ensure reliable data interpretation.

What enabled the evolution of TIL therapies? What does the future hold for them? And where should you concentrate your efforts to accelerate progress? Watch for answers to these questions and more.

Discover how JAG201, an innovative AAV9-based gene therapy, transforms the treatment landscape for patients with Phelan-McDermid syndrome and SHANK3 haploinsufficiency.

The landscape of cell and gene therapy is advancing rapidly, revolutionizing healthcare by offering novel treatments for cancer, rare genetic conditions, and hematological diseases.

Early product characterization can serve to uncover crucial information about an advanced therapeutic candidate, affording new insight into its CQAs and helping to shape better analytical assays.

Incorporating novel nucleases into CRISPR therapies enhances intellectual property benefits through improved licensing, strategic protections, and access to new gene targets.

Listen in on this session from The State of CRISPR and Gene Editing Summit which focus on the use of CRISPR-based therapies in clinical settings using electroporation. 

Monoclonal antibodies (mAbs) stand as pivotal drug products and biochemical reagents in the 21st century. Explore how mRNA-encoded antigens could revolutionize antibody discovery.

Concerns about in vitro relevance and animal study limits have advanced cell culture tech. Consider how Organ-Chips offer a refined approach to studying human physiology.

Examine the usability and performance capabilities of a system that provides a streamlined flow cytometry workflow, from instrument initialization to data acquisition and analysis.

Learn about an approach to method development, where more than one AAV critical quality attribute can be measured within a single analytical run.